Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
American Society of Hematology (ASH)
The
American Society of Hematology
(
ASH
) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal
Blood
, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal,
Blood Advances
.
Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
Researchers reported results of a population-based study examined sex, race, and age-stratified differences in incidence, mortality, and survival from 1973 to 2012 for 89,867 myeloma patients by using national epidemiologic data.
Read More ›
The Significant Contribution of Pain in Determining the Health Status of Patients with Multiple Myeloma
Researchers presented results of patient-reported assessments of general health status as well as pain severity and interference using pooled data from 3 denosumab registrational trials that had enrolled patients with advanced cancers including multiple myeloma (MM).
Read More ›
Incidence of Falls Is Common in Older Adults with Newly Diagnosed MM
Researchers reported results of an analysis using national epidemiologic data and self-reported data from the Medicare Health Outcomes Survey that determined the prevalence of falls in older adults with newly diagnosed multiple myeloma (MM) and examined associations between falls and functional status, comorbidities, and self-reported health.
Read More ›
Improving the Management of Patients on Oral Regimens
Beth Faiman elaborates on her idea wish list of resources and tools that would help her to better manage patients on oral oncolytics.
Read More ›
Combination Therapy for Patients with CLL
Updated findings from a study of ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia (CLL), focusing specifically on the results of minimal residual disease testing.
Read More ›
Preliminary Evidence for Identifying Patterns of Organ Damage in Advanced Systemic Mastocytosis Subtypes
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials.
Read More ›
Gilteritinib and Azacitidine versus Azacitidine for Newly Diagnosed FLT3-Mutated AML in Patients Ineligible for Intensive Induction Chemotherapy
ASH 2021 – AML
Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed
FLT3
mut+
AML ineligible for intensive induction chemotherapy.
Read More ›
Prognostic Value of MRD in AML Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation in First versus Second Morphologic Remission
ASH 2021 – AML
MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML.
Read More ›
Cladribine as First-Line Therapy for Indolent and Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge.
Read More ›
First-in-Human Study of Menin Inhibitor SNDX-5613 in MLL-Rearranged and NPM1-Mutant Acute Leukemia
ASH 2021 – AML
In the first-in-human phase 1/2 AUGMENT 101 study, SNDX-5613 demonstrated an acceptable safety profile and promising antileukemic activity in patients with heavily pretreated relapsed/refractory
MLL
-rearranged and
NPM1
-mutated acute leukemias.
Read More ›
Page 6 of 44
1
2
3
4
5
6
7
8
9
10
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us